We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
+24.92%
1 Year Est. Return
+18.48%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$126M
AUM Growth
+$9.73M
Cap. Flow
+$224M
Cap. Flow %
177.31%
Top 10 Hldgs %
37.67%
Holding
493
New
153
Increased
113
Reduced
67
Closed
127

Sector Composition

1 Healthcare 39.95%
2 Consumer Staples 5.72%
3 Consumer Discretionary 5.14%
4 Technology 3.35%
5 Materials 2.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MAT icon
426
CALL
Mattel
MAT
$4.26B
-50,000
Closed -$323K
MCD icon
427
CALL
McDonald's
MCD
$194B
-35,000
Closed -$6K
MMM icon
428
CALL
3M
MMM
$84.4B
-46,644
Closed -$130K
MNST icon
429
CALL
Monster Beverage
MNST
$97.7B
-151,200
Closed -$221K
MNST icon
430
PUT
Monster Beverage
MNST
$97.7B
-70,800
Closed -$54K
MOS icon
431
The Mosaic Company
MOS
$7.16B
-8,600
Closed -$225K
ODP
432
CALL
DELISTED
ODP
ODP
-2,350
Closed -$1K
OPK icon
433
Opko Health
OPK
$899M
-3,000
Closed -$28K
OPK icon
434
PUT
Opko Health
OPK
$899M
-12,200
Closed -$9K
PRGO icon
435
CALL
Perrigo
PRGO
$1.54B
-77,000
Closed -$6K
PRQR icon
436
ProQR Therapeutics
PRQR
$236M
-12,523
Closed -$61K
QCOM icon
437
Qualcomm
QCOM
$180B
-2,100
Closed -$128K
QRVO icon
438
CALL
Qorvo
QRVO
$7.37B
-12,000
Closed -$20K
RCKT icon
439
CALL
Rocket Pharmaceuticals
RCKT
$372M
-42,075
Closed -$17K
RGLS
440
CALL
DELISTED
Regulus Therapeutics
RGLS
-797
Closed -$7K
RGLS
441
DELISTED
Regulus Therapeutics
RGLS
-42
Closed -$14K
RGLS
442
PUT
DELISTED
Regulus Therapeutics
RGLS
-42
Closed -$24K
RIGL icon
443
CALL
Rigel Pharmaceuticals
RIGL
$771M
-2,000
Closed -$4K
RMBS icon
444
Rambus
RMBS
$11B
-5,200
Closed -$63K
RMBS icon
445
PUT
Rambus
RMBS
$11B
-5,200
Closed -$11K
SAGE
446
CALL
DELISTED
Sage Therapeutics
SAGE
-15,300
Closed -$32K
SAGE
447
PUT
DELISTED
Sage Therapeutics
SAGE
-10,000
Closed -$18K
SO icon
448
PUT
Southern Company
SO
$108B
-5,000
Closed -$2K
SVXY icon
449
CALL
ProShares Short VIX Short-Term Futures ETF
SVXY
$219M
-77,500
Closed -$218K
SVXY icon
450
PUT
ProShares Short VIX Short-Term Futures ETF
SVXY
$219M
-20,000
Closed -$1K

Similar funds

FT Options's Q3 2016 Portfolio in Review

As of Q3 2016, FT Options held 493 positions worth $126M, up 8.4% from $116M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

FT Options deployed $224M of net new capital in Q3 2016, opening 153 new positions and adding to 113 existing holdings. Its largest new stake was iShares Biotechnology ETF: 21,000 shares worth $2.03M.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 41% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Apple, an estimated $2.74M trimmed.

  • FT Options's largest Q3 2016 buy was iShares Biotechnology ETF: 21,000 shares worth $2.03M.
  • FT Options added most to Procter & Gamble in Q3 2016, an estimated $3.82M increase.
  • FT Options's biggest Q3 2016 reduction was Apple, cutting an estimated $2.74M.
  • FT Options fully exited MEDIVATION, INC. in Q3 2016, selling an estimated $7.18M.
  • FT Options's ten largest holdings make up 38% of its $126M portfolio in Q3 2016.
  • FT Options opened 153 new positions and closed 127 in Q3 2016.
  • FT Options's portfolio value rose 8.4% quarter-over-quarter to $126M.

Based on FT Options's 13F filing for Q3 2016, filed 10 Nov 2016.